David A. Roth
0000-0001-8356-0457
Publication & Citation Trends
Publications
0 total
Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS
Cited by 7
Semantic Scholar
A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemia
Cited by 4
Semantic Scholar
SELECT-AML-1: Phase 2 Randomized Trial of Tamibarotene in Combination With Venetoclax and Azacitidine in Adult Patients With Previously Untreated AML With RARA Overexpression, Who Are Ineligible for Standard Induction Therapy
Cited by 0
Semantic Scholar
AML-347 SELECT-AML-1: Phase 2 Randomized Trial of Tamibarotene in Combination With Venetoclax and Azacitidine in Adult Patients With Previously Untreated AML With RARA Overexpression, Who Are Ineligible for Standard Induction Therapy
Cited by 1
Semantic Scholar
Phase 1/1b study of SY-5609, a selective and potent CDK7 inhibitor, in advanced solid tumors and in 2L/3L pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine +/- nab-paclitaxel.
Cited by 2
Semantic Scholar
PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY OA
Cited by 0
Semantic Scholar
Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression OA
Cited by 7
Semantic Scholar
Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: SELECT-MDS-1 TRIAL IN PROGRESS: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF TAMIBAROTENE/AZACITIDINE VS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED (ND) ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS
Cited by 0
Semantic Scholar
Research Topics
Systemic Lupus Erythematosus Research
(89)
Monoclonal and Polyclonal Antibodies Research
(56)
T-cell and B-cell Immunology
(31)
Renal Transplantation Outcomes and Treatments
(31)
Renal Diseases and Glomerulopathies
(22)
Affiliations
Marquette University
University of North Carolina at Chapel Hill
Tufts University
United States Nuclear Regulatory Commission
Tufts Medical Center